Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CN54gp140 + GLA-AF (Imperial College London, b372a9)
- Development stage
- Phase 1
- Lead developer
- Imperial College London
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
CN54gp140 + GLA-AF is an experimental HIV vaccine candidate consisting of a trimeric recombinant envelope glycoprotein (gp140) derived from the HIV-1 clade C strain 97CN54, formulated with the adjuvant GLA-AF (glucopyranosyl lipid adjuvant-aqueous formulation). Developed by Imperial College London and the UK HIV Vaccine Consortium, the vaccine aims to induce protective immune responses, including envelope-specific binding antibodies and mucosal immunity, against HIV-1. GLA-AF acts as a Toll-like receptor 4 (TLR4) agonist to enhance the immunogenicity of the protein subunit. It has been primarily evaluated in Phase 1 clinical trials, often as a boost in prime-boost regimens involving DNA or MVA-based vaccines.
- Other names
- 97CN54gp140CN54 gp140CN-54 gp140CN 54 gp140HIV-1 clade C strain 97CN54 gp140HIV1 clade C strain 97CN54 gp140HIV 1 clade C strain 97CN54 gp140
02
Targets
CD14 (Monocyte differentiation antigen CD14)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)LY96 (Myeloid differentiation factor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on CN54gp140 + GLA-AF (Imperial College London, b372a9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CN54gp140 + GLA-AF (Imperial College London, b372a9).